Multisystem inflammatory syndrome drug treatment in countries with different income profiles: a scoping review

Frontiers in Pharmacology

Pharmacology

Alice Ramos Oliveira Silva¹  Lidiane Gomes da Cunha¹  Elisangela Costa Lima¹  Luis Phillipe Nagem Lopes²  Luciane Cruz Lopes²  Adriana Rodrigues Fonseca³  Marcelo Gerardin Poirot Land³ 

[1] Faculty of Pharmacy, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil;Post-Graduate Program in Pharmaceutical Sciences, University of Sorocaba, São Paulo, Brazil;Post-Graduate Program in Saúde Materno Infantil, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil;

关键词: multisystem inflammatory syndrome in children;    social determinants of health;    COVID-19;    high-cost medicines;    pediatrics;   

DOI  :  10.3389/fphar.2023.1228986

 received in 2023-05-25, accepted in 2023-08-08,  发布年份 2023

来源: Frontiers

【 摘 要 】

Objective: The purpose of this study was to map and describe the studies that have investigated therapeutic alternatives for the management of paediatric multisystem inflammatory syndrome in children (MIS-C) associated with COVID-19. Considering the origin of the studies performed (low-, middle- and high-income countries), a systematic scoping review was conducted with primary studies that reported the use of medications for the treatment of patients with MIS-C.Sources: The searches were performed in MEDLINE, Embase, Lilacs, Epistemonikos, CINAHL, and CENTRAL, in the grey literature (theses and dissertations from CAPES, ProQuest, and PROSPERO) and in clinical trial databases until May 2022. The selection and extraction of studies were performed independently by two reviewers.Summary of the findings: A total of 173 studies were included, most of which were published as case reports or series. No randomized controlled clinical trials (RCTs) were identified. The investigated drugs were immunoglobulins, glucocorticoids, monoclonal antibodies, anticoagulants, and antiplatelet agents.Conclusion: The dosages, when reported, were heterogeneous among the studies. The ethnicity and comorbidity of the participants were poorly reported. Monoclonal antibodies, drugs with higher costs, were mostly described in studies of high-income countries.

【 授权许可】

Unknown   
Copyright © 2023 Nagem Lopes, da Cunha, Silva, Land, Fonseca, Lopes and Lima.